Meanwhile, JQ1 is a prototype BRD4 inhibitor with proven therapeutic benefits in MM [94], AML [95], diffuse large B-cell lymphoma (DLBCL) [96], prostate cancer [97], and breast cancer [98]. This evidence concerns the gene BRD4 and Miyoshi myopathy.